Asklepios BioPharmaceutical, Inc.
https://www.askbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Asklepios BioPharmaceutical, Inc.
Bayer Puts Spotlight On Pharma Pipeline
The Leverkusen-based firm has been touting the potential of its pharmaceutical pipeline which it hopes will be able to help soften the blow of patent expiries on the blockbusters Xarelto and Eylea in the next few years.
Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer
The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.
Bayer Bids To Be A Winner In Cell & Gene Therapy
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.
Bayer Enters CAR-T Space With Atara Pact
Marianne De Backer, head of pharma BD and licensing at the German firm, told Scrip, "We strongly believe that the future is allogeneic and we were looking for pioneers in the field."
Company Information
- Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- Actus Therapeutics, Inc.
- AskBio
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
- BrainVectis